Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab
about
Mechanisms underlying skin disorders induced by EGFR inhibitorsNew findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?Different treatment strategies and molecular features between right-sided and left-sided colon cancersMeta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancerPrediction of response to anti-EGFR antibody-based therapies by multigene sequencing in colorectal cancer patients.Role of targeted therapy in metastatic colorectal cancerCurrent approaches for predicting a lack of response to anti-EGFR therapy in KRAS wild-type patientsMismatch repair deficiency endows tumors with a unique mutation signature and sensitivity to DNA double-strand breaks.Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies.A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancerMeta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival.Right-sided colon cancer and left-sided colorectal cancers respond differently to cetuximab.Molecular spectrum of KRAS, NRAS, BRAF and PIK3CA mutations in Chinese colorectal cancer patients: analysis of 1,110 cases.Molecular pathological epidemiology of colorectal cancer in Chinese patients with KRAS and BRAF mutationsVariation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease.Molecular spectrum of KRAS, NRAS, BRAF, PIK3CA, TP53, and APC somatic gene mutations in Arab patients with colorectal cancer: determination of frequency and distribution pattern.Anti-EGFR MoAb treatment in colorectal cancer: limitations, controversies, and contradictories.Current controversies in the management of metastatic colorectal cancer.Incorporating traditional and emerging biomarkers in the clinical management of metastatic colorectal cancer.New Therapeutic Opportunities Based on DNA Mismatch Repair and BRAF Status in Metastatic Colorectal Cancer.Primary tumor site and anti-EGFR monoclonal antibody benefit in metastatic colorectal cancer: a meta-analysis.The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.BRAF Mutations as Predictive Biomarker for Response to Anti-EGFR Monoclonal Antibodies.EGFR, BRAF and KRAS status in patients undergoing pulmonary metastasectomy from primary colorectal carcinoma: a prospective follow-up study.Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives.Mutations in the RAS and PI3K pathways are associated with metastatic location in colorectal cancers.Incorporating Biomarker Stratification into STAMPEDE: an Adaptive Multi-arm, Multi-stage Trial Platform.Molecular spectrum of KRAS, BRAF, and PIK3CA gene mutation: determination of frequency, distribution pattern in Indian colorectal carcinoma.Prognostic value of the combination of microsatellite instability and mutation in colorectal cancer
P2860
Q26745689-93056C6C-E640-4D6F-9512-28BE954098CEQ26796348-0450079E-2B94-41C2-B702-4EF65A1B5255Q26865322-5E25A320-C479-466F-9648-0C81668242BBQ27027648-2F93B994-A080-4FA5-B81D-C73AAD16DC8EQ27853234-D3C9F5E3-187D-432F-9F65-BED84ED939DFQ28068817-B9110863-2D03-4444-97B7-91F999E022D0Q33861210-BE8368FB-5C99-464F-A1F5-F88A9A9A1892Q34077139-F90042FD-4F09-4B25-B69E-5A0CEA731EAEQ34362289-74A57AA3-0B7A-4A02-BD58-B09AAED0B068Q35626744-52D519E9-97B4-4EED-B197-C9C00AEBFF1CQ35709696-ED2A7316-F636-4A8F-AE8C-DD6BA81D47C6Q35921785-20A99E4C-544E-47A8-A39D-72A56E51E422Q36121090-E3A8C59E-95F9-4C5D-8BB4-7EE9F7120E1EQ36393095-C69080EF-F945-4AB6-B820-E7E025E2802FQ36545430-D08CEA40-6A3F-4455-A132-A42E064AB1C9Q37367984-570866B3-509E-48C9-BC8F-67BBEABFA14BQ37525272-8363109A-E637-4F99-BADC-382A402B14E5Q38219290-56D6F689-9E52-45C7-886C-F959CA247C39Q38538213-74C0A497-31EC-4376-B491-0F42EDD3799FQ38545768-E7E77851-824B-4446-9EF2-60597C7A36DEQ38727912-9CF6C176-FA62-42C1-BB3F-502765E27C08Q38767373-6E1D6CFE-8D6F-4918-9F66-FEC7CEC8B358Q38880745-D65E0473-79E1-4550-B9BE-66A6D3978A43Q39347386-0C83DCBD-CBC8-46AF-9902-AE570E1A034BQ42252801-35A53D60-34A4-4301-AD03-84E966AD049FQ44995693-3F044F21-CCC6-4E62-9E65-311BF5D9EA47Q47767987-E56E256C-051D-43D4-8CE6-191939D3C008Q48084362-5758F0FB-0984-4C6F-B2D6-E2AAC9077882Q50099775-3031CF13-1577-4B3A-BE56-3DDDE338673FQ54334205-92C45187-0861-4C3F-BA6C-893E49E73A57Q57491315-5A9E9058-7C69-4209-A31B-15B617137BB9
P2860
Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Somatic profiling of the epide ...... with chemotherapy ± cetuximab
@en
Somatic profiling of the epide ...... with chemotherapy ± cetuximab.
@nl
type
label
Somatic profiling of the epide ...... with chemotherapy ± cetuximab
@en
Somatic profiling of the epide ...... with chemotherapy ± cetuximab.
@nl
prefLabel
Somatic profiling of the epide ...... with chemotherapy ± cetuximab
@en
Somatic profiling of the epide ...... with chemotherapy ± cetuximab.
@nl
P2093
P2860
P921
P1476
Somatic profiling of the epide ...... with chemotherapy ± cetuximab
@en
P2093
Angela Meade
Bart Claes
Bharat Jasani
Christopher G Smith
David Fisher
Gilian Peuteman
Jeremy P Cheadle
Michelle D James
Rebecca Harris
Richard A Adams
P2860
P304
P356
10.1158/1078-0432.CCR-12-2581
P407
P577
2013-06-05T00:00:00Z